Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Johann De Bono’

Prostate Cancer Session at AACR-NCI-EORTC Molecular Targets San Francisco

By on November 17, 2011

San Francisco Cable Car 300x225 Prostate Cancer Session at AACR NCI EORTC Molecular Targets San FranciscoThe recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference in San Francisco was an informative meeting.

What I particularly liked was the strategic overview that took place in many of the plenary sessions.

As an example, Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research/The Royal Marsden in London highlighted the potential drug development targets based on prostate cancer biology:

  • Androgen Receptor (AR)
  • Heat Shock Proteins (Hsp)
  • Signaling: HER3, MET, IGF-1R, CCL2, IL-6, Src
  • PI3K/AKT/TOR signaling
  • PARP and BRCAness
  • Estrogen receptor (ER)
  • c-MYC & CHK1
This is a preview of Prostate Cancer Session at AACR-NCI-EORTC Molecular Targets San Francisco. Read the full post

Leave a comment

Insights from Society for Translational Oncology Prostate Cancer Symposium

By on October 31, 2011

The Oncologist Journal of the Society for Translational Oncology (STO) has published a video recording on prostate cancer that is well worth watching for those with an interest in this area.

At their Sept 8, 2011 CME symposium held in Belfast, a roundtable was held entitled “Prostate Cancer: Progress & Promise.”

Moderated by Bruce A. Chabner (Mass General/Harvard), the panelists were Joe O’Sullivan (Queen’s University, Belfast), Johann De Bono (The Institute for Cancer Research) and David Waugh (Queen’s University, Belfast).

Professor de Bono in the video comments that”

This is a preview of Insights from Society for Translational Oncology Prostate Cancer Symposium. Read the full post

Leave a comment

Emerging new therapies for advanced metastatic Prostate Cancer

By on March 20, 2011

EAU Vienna 2011 300x225 Emerging new therapies for advanced metastatic Prostate Cancer Today at the European Association of Urology (EAU) annual meeting in Vienna, the big news was that 2010 was a “Grand Cru” year for new treatments for advanced prostate cancer.  Not only that, but sanofi-aventis announced that they had received European marketing approval for cabazitaxel (Jevtana®) in metastatic hormone resistance prostate cancer mHRPC.

The fact that there are now several new treatments available (or expected to be available in the not too distant future) is good news for patients and physicians.

This is a preview of Emerging new therapies for advanced metastatic Prostate Cancer. Read the full post

2 Comments